Combination of Rituximab and NK Immunotherapy for B Lymphoma

Sponsor
Fuda Cancer Hospital, Guangzhou
Study ID
NCT02843061
Phase
PHASE1/PHASE2
Status
Completed

Conditions

  • B-cell Lymphoma Recurrent

Eligibility Criteria

Sex
ALL
Age
30 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • Rituximab — DRUG
  • NK immunotherapy — BIOLOGICAL
    Each time 10 billion cells, 4 times in all,i.v.

Study Details

The aim of this study is the safety and efficacy of Rituximab plus NK immunotherapy to recurrent B lymphoma.

Key Dates

Start date
Jul 1, 2016
Status verified
Jul 2019
Primary completion
Jul 1, 2017
Completion
Jul 1, 2019

Study Design

Enrollment
30 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Rituximab and NK immunotherapy
    In this group, the patients will receive regular Rituximab treatment accompanied with multiple NK immunotherapy. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
  • Active Comparator: Rituximab
    In this group, the patients will receive regular Rituximab to decrease tumor burden. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).

Primary Outcome Measure

Relief degree evaluated by the RECIST [ Time Frame: 3 months ]